Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track CALC with free AI briefings, catalyst countdowns, and dilution alerts.

CALC · CalciMedica, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$13.8M Cash on Hand
9.7mo Cash Runway
Follow CALC by email Get an email when CALC reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about CALC, unsubscribe in one click. Privacy

📣 What CALC Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Auxora Acute Kidney Injury Phase 2 · NCT06374797 Terminated
Zegocractin (CM4620) Acute Pancreatitis Phase 2 · NCT04681066 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

CALC holds $13.8M in cash and short-term investments (as of Sep 30, 2026) and burns about $4.2M/quarter from operations, an estimated runway of 9.7 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 70 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CALC files for a raise →

👥 Who Owns CALC

Insiders 100% Institutions 0% Public and other holders 0%
HolderTypeShares% of sharesAs of
ALAFI CAPITAL CO LLC
10% owner · +7.06M options
Insider 5,112,345 74.14% 2026-08-19
Bering Partners II GP, L.L.C. 5%+ holder (13D) 3,553,398 51.53% 2026-08-19
Fred A Middleton
Director, 10% owner
Insider 2,700,834 39.17% 2026-06-25
Woodline Partners LP Institution (13G, 5%+) 2,489,729 36.11% 2026-06-30
Evgeny Zaytsev
Director · +2.95M options
Insider 2,113,513 30.65% 2026-07-02
Robert N Wilson
Director · +2.40M options
Insider 1,604,650 23.27% 2026-06-25
Eric W Roberts
CHIEF BUSINESS OFFICER, Director · +694,566 options
Insider 1,250,466 18.14% 2026-06-25
A. Rachel Leheny
CHIEF EXECUTIVE OFFICER, Director · +881,940 options
Insider 1,061,481 15.39% 2026-06-25
StemPoint Capital LP Institution (13G, 5%+) 730,223 10.59% 2026-09-30
Stonepine Capital Management, LLC Institution (13G, 5%+) 579,912 8.41% 2026-09-30
Armistice Capital, LLC Institution (13G, 5%+) 388,641 5.64% 2026-09-30
Sudarshan Hebbar
Chief Medical Officer · +520,145 options
Insider 186,025 2.70% 2026-06-25

Share count 6,895,149 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full CALC picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CALC and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.